Clinical Trials Directory

Trials / Unknown

UnknownNCT04948242

Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

Epidemiologic, Clinical Characteristics and Risk Factors of Critical Ill Patients Admitted to the ICU for Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

Status
Unknown
Phase
Study type
Observational
Enrollment
5,000 (estimated)
Sponsor
Hospital Universitari Joan XXIII de Tarragona. · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

A multicenter observational, prospective cohort study that consisted of a large-scale data source of hospital ICU admissions and patient-level clinical data in Spain. The main objective is to develop a national database belonging to SEMICYUC (Spanish Society of Critical Care) to describe epidemiological and clinical characteristics and risk factors related to ICU mortality in critically ill patients admitted to ICU due to severe COVID-19 in Spain.

Detailed description

Design: A multicenter observational, prospective cohort study Setting: Intensive Care Units Subjects: Adult Critical patients admitted to ICU with severe community-acquired pneumonia due to confirmed SARS CoV-2 infection (COVID-19). Data Collection and Validation Data was obtained from a voluntary registry created by Spanish Society of Intensive Care Medicine-SEMICYUC. All consecutive cases admitted to the ICU were collected. There were no patients excluded from the analysis that was enrolled to participating ICU and met criteria. Data were collected using a paper CRF (case Report Form). CRF collect and record all protocol-required information, which is transcribed from patient source documents, such as hospital records and laboratory reports during the patient's participation in the study. Before being sent to the National Study Coordinator (AR) this data was de-identified (not traceable to the patient) by removing the patient's name, medical record number, etc., and giving the patient a unique study number. We implemented a double data entry model for potential errors in real-time. Data was entered twice by two different Data Entry personnel based on the same set of data collected in the paper CRFs. All data were reviewed, and values that appeared incongruent or out of range were manually validated by confirming the accuracy of the data with the Study Coordinator (AR). The database was validated and cleaned before the statistical analysis and the study database was locked to prevent any further changes, and to ensure data consistency and integrity for the statistical reporting and analysis. Sample size calculation: No statistical sample size calculation was performed a priori, and sample size was equal to the number of patients admitted to the participant's ICUs with confirmed COVID-19 during the study period.

Conditions

Timeline

Start date
2019-12-12
Primary completion
2023-04-17
Completion
2023-12-31
First posted
2021-07-01
Last updated
2023-04-20

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT04948242. Inclusion in this directory is not an endorsement.